Inhibikase Therapeutics is a clinical-stage company developing small molecule kinase inhibitors for cardiopulmonary diseases. Its lead program IkT-001, a prodrug formulation of imatinib, targets pulmonary arterial hypertension. The company has shifted emphasis from earlier neurodegenerative disease programs to this orphan cardiopulmonary indication.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -13.7 | — |
| Q2 2025 | 0 | — | -9.9 | — |
| Q3 2025 | 0 | — | -11.9 | — |
| Q4 2025 | 0 | — | -12.7 | — |
| Q1 2026 | 0 | — | -16.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: John Marshall Bancorp, Inc. (JMSB), Aldel Financial II Inc. (ALDF), Irenic Acquisition Corp. (IACQ), Cantor Equity Partners VII, Inc. (CAES), Perimeter Acquisition Corp. I (PMTR), Sanara MedTech Inc. (SMTI)